Viatris Japan, Australia and New Zealand Segment — Operating Income (Loss) decreased by 7.8% to $64.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.0%, from $62.20M to $64.70M. Over 2 years (FY 2021 to FY 2023), Japan, Australia and New Zealand Segment — Operating Income (Loss) shows a downward trend with a -17.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates improved regional profitability, while a decrease suggests margin compression or declining sales performance.
This metric measures the profitability of the Japan, Australia, and New Zealand segment by subtracting the cost of sales...
Comparable to regional operating profit metrics reported by peers in the pharmaceutical sector.
vtrs_segment_japan_australia_and_new_zealand_segment_operating_income_loss| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $185.40M | $216.70M | $176.10M | $174.30M | $158.10M | $163.60M | $169.50M | $130.50M | $131.60M | $125.40M | $135.40M | $87.30M | $101.30M | $102.90M | $62.20M | $83.70M | $70.20M | $64.70M |
| QoQ Change | — | +16.9% | -18.7% | -1.0% | -9.3% | +3.5% | +3.6% | -23.0% | +0.8% | -4.7% | +8.0% | -35.5% | +16.0% | +1.6% | -39.6% | +34.6% | -16.1% | -7.8% |
| YoY Change | — | — | — | — | -14.7% | -24.5% | -3.7% | -25.1% | -16.8% | -23.3% | -20.1% | -33.1% | -23.0% | -17.9% | -28.8% | -17.4% | -31.8% | +4.0% |